Your browser doesn't support javascript.
loading
A Comprehensive Analysis of LYAR in Colorectal Cancer: Prognostic Marker and Therapeutic Target.
Wen, Jia-Ying; Fang, Ye-Ying; Li, Dong-Ming; Tang, Yu-Lu; Huang, He-Qing; Liu, Li-Min; Zeng, Jiang-Hui; Dang, Yi-Wu; Pan, Yan-Fang; Zeng, Da-Tong; Huang, Wei-Jian; Chen, Gang; Li, Hui.
Afiliación
  • Wen JY; Department of Radiotherapy, The Second Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
  • Fang YY; Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
  • Li DM; Department of Pathology, Guangxi Key Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
  • Tang YL; Department of Pathology, Guangxi Key Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
  • Huang HQ; Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
  • Liu LM; Department of Toxicology, College of Pharmacy, Guangxi Medical University, Nanning, P.R. China.
  • Zeng JH; Department of Clinical Laboratory, The Third Affiliated Hospital of Guangxi Medical University/Nanning Second People's Hospital, Nanning, P. R. China.
  • Dang YW; Department of Pathology, Guangxi Key Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
  • Pan YF; Department of Pathology, Hospital of Guangxi Liugang Medical Co., LTD./Guangxi Liuzhou Dingshun Forensic Expert Institute, Liuzhou, P.R. China.
  • Zeng DT; Department of Pathology, Redcross Hospital of Yulin city, Yulin, P.R. China.
  • Huang WJ; Department of Pathology, Redcross Hospital of Yulin city, Yulin, P.R. China.
  • Chen G; Department of Pathology, Guangxi Key Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
  • Li H; Department of Colorectal & Anal Surgery, Guangxi Key Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
Cancer Biother Radiopharm ; 2024 Aug 19.
Article en En | MEDLINE | ID: mdl-39159060
ABSTRACT

Background:

Colorectal cancer (CRC) is a major global health challenge with a need for new biomarkers and therapeutic targets. This work aimed to investigate the biological mechanisms and clinical value of Ly1 antibody reactive (LYAR) in CRC.

Methods:

We analyzed LYAR mRNA expression across multiple public databases, including genotype-tissue expression, gene expression omnibus, Oncomine, and the cancer genome atlas, alongside in-house immunohistochemical data to evaluate LYAR protein expression in CRC and non-CRC colorectal tissues. Gene set enrichment analysis (GSEA) was used to elucidate LYAR's biological functions, and its impact on the tumor immune microenvironment was assessed using CIBERSORT, ESTIMATE, and single-cell RNA sequencing techniques. In addition, LYAR's association with clinicopathological features and patient prognosis was explored, and its influence on drug sensitivity was investigated using the Connectivity Map database.

Results:

LYAR was significantly upregulated in CRC tissues compared with non-CRC colorectal counterparts, associated with altered immune cell composition and enhanced RNA processing, splicing, and cell cycle regulation. High LYAR expression correlated with poor disease-free and overall survival, underscoring its prognostic value. GSEA revealed LYAR's involvement in critical cellular processes and pathways, including DNA repair, cell cycle, and mTORC1 signaling. Correlation analysis identified genes positively and negatively associated with LYAR, leading to the discovery of temsirolimus and WYE-354, mTOR inhibitors, as potential therapeutic agents for CRC. Furthermore, LYAR expression predicted increased sensitivity to cetuximab in RAS wild-type metastatic CRC, indicating its utility as a biomarker for treatment responsiveness.

Conclusions:

LYAR's upregulation in CRC highlights its potential as a biomarker for prognosis and therapeutic targeting, offering insights into CRC pathology and suggesting new avenues for treatment optimization.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Biother Radiopharm Asunto de la revista: FARMACIA / FARMACOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Biother Radiopharm Asunto de la revista: FARMACIA / FARMACOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos